Atrial Fibrillation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Atrial Fibrillation (US)
Atrial fibrillation (AF) is a common arrhythmia characterized by irregular, often rapid heartbeats in the atria, increasing the risk of stroke and cardiovascular complications. Management typically involves polypharmacy to mitigate the risk of stroke, control the heart rate, and restore normal cardiac rhythm. Treatment regimens often include rate-control medications such as metoprolol or diltiazem and direct oral anticoagulants (DOACs) such as Eliquis or Xarelto, either as stand-alone therapies or in combination. Antiarrhythmic agents (e.g., amiodarone, flecainide) are typically reserved for later stages of treatment due to their potential adverse effects. This report analyzes real-world claims data to provide insight into prescribing trends for newly diagnosed and recently treated AF patients, with further analyses examining patients’ persistency and compliance with medication examining patients’ persistency and compliance with medication.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AF patients?
- How have DOACs been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of AF patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What percentage of AF patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key companies: Cardinal Health, Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Daiichi Sankyo, Boehringer Ingelheim, Pfizer, Baxter Healthcare, Validus Pharmaceuticals, Waylis Therapeutics, Bayer Healthcare
Key drugs: Vitamin K antagonists; oral direct factor Xa inhibitors; class Ia, Ic, and III antiarrhythmics; beta blockers; calcium channel blockers; digitalis glycosides; antiplatelet agents
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.Dashboard featuring interactive visuals, easy navigation, and expanded analyses.
